Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2011 (2011), Article ID 471214, 7 pages
http://dx.doi.org/10.4061/2011/471214
Review Article

Dilemma of HCV Infection in Renal Transplant Recipients

Urology and Nephrology Center, Mansoura University, Gomhoria Street, Mansoura, Egypt

Received 14 November 2010; Revised 19 January 2011; Accepted 5 March 2011

Academic Editor: Ayman Karkar

Copyright © 2011 Osama Ashry Ahmed Gheith. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. J. Pereira, S. N. Natov, B. A. Bouthot et al., “Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease,” Kidney International, vol. 53, 1374 pages, 1998. View at Google Scholar
  2. D. Roth, “Hepatitis C virus: the nephrologist's view,” American Journal of Kidney Diseases, vol. 25, no. 1, pp. 3–16, 1995. View at Google Scholar
  3. J. M. Morales and J. M. Campistol, “Transplantation in the patient with hepatitis C,” Journal of the American Society of Nephrology, vol. 11, no. 7, pp. 1343–1353, 2000. View at Google Scholar · View at Scopus
  4. G. G. Vosnides, “Hepatitis C in renal transplantation,” Kidney International, vol. 52, no. 3, pp. 843–861, 1997. View at Google Scholar · View at Scopus
  5. “European best practice guidelines for renal transplantation (part 1). Section I: evaluation, selection and preparation of the potential recipient,” Nephrology Dialysis Transplantation, vol. 15, supplement 7, pp. 1–85, 2000.
  6. “KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease,” Kidney International, vol. 73, supplement 109, pp. S1–S99, 2008.
  7. A. Covic, D. Abramowicz, A. Bruchfeld et al., “Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement,” Nephrology Dialysis Transplantation, vol. 24, no. 3, pp. 719–727, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. J. M. Morales, B. Domínguez-Gil, D. Sanz-Guajardo, J. Fernández, and F. Escuin, “The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure,” Nephrology Dialysis Transplantation, vol. 19, supplement 3, pp. iii72–iii76, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. Juszczyk, “Fifteen years of investigations on hepatitis C virus in Poland,” Przegląd epidemiologiczny, vol. 59, no. 2, pp. 373–384, 2005. View at Google Scholar · View at Scopus
  10. N. N. Zein, “Clinical significance of hepatitis C virus genotypes,” Clinical Microbiology Reviews, vol. 13, no. 2, pp. 223–235, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. A. S. Abdulkarim, N. N. Zein, J. J. Germer et al., “Hepatitis C virus genotypes and hepatitis G virus in hemodialysis patients from Syria: identification of two novel hepatitis C virus subtypes,” American Journal of Tropical Medicine and Hygiene, vol. 59, no. 4, pp. 571–576, 1998. View at Google Scholar · View at Scopus
  12. R. W. Chamberlain, N. Adams, A. A. Saeed, P. Simmonds, and R. M. Elliott, “Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East,” Journal of General Virology, vol. 78, no. 6, pp. 1341–1347, 1997. View at Google Scholar · View at Scopus
  13. E. L. Murphy, S. M. Bryzman, S. A. Glynn et al., “Risk factors for hepatitis C virus infection in United States blood donors,” Hepatology, vol. 31, no. 3, pp. 756–762, 2000. View at Google Scholar · View at Scopus
  14. B. J. Pereira and A. S. Levey, “Hepatitis C virus infection in dialysis and renal transplantation,” Kidney International, vol. 51, no. 4, pp. 981–999, 1997. View at Google Scholar
  15. J. Y. Lau, G. L. Davis, M. E. Brunson et al., “Hepatitis C virus infection in kidney transplant recipients,” Hepatology, vol. 18, no. 5, pp. 1027–1031, 1993. View at Publisher · View at Google Scholar
  16. B. J. Pereira, S. N. Natov, B. A. Bouthot et al., “Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group,” Kidney International, vol. 53, no. 5, pp. 1374–1381, 1998. View at Publisher · View at Google Scholar · View at PubMed
  17. D. Roth, K. Zucker, R. Cirocco et al., “A prospective study of hepatitis C virus infection in renal allograft recipients,” Transplantation, vol. 61, no. 6, pp. 886–889, 1996. View at Publisher · View at Google Scholar
  18. L. Rostaing, J. Izopet, K. Sandres, J. M. Cisterne, J. Puel, and D. Durand, “Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil,” Transplantation, vol. 69, no. 5, pp. 991–994, 2000. View at Google Scholar
  19. D. B. Strader, T. Wright, D. L. Thomas, and L. B. Seeff, “Diagnosis, management, and treatment of hepatitis C,” Hepatology, vol. 39, no. 4, pp. 1147–1171, 2004. View at Publisher · View at Google Scholar · View at PubMed
  20. F. Fabrizi, P. Martin, V. Dixit, S. Bunnapradist, and G. Dulai, “Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies,” American Journal of Transplantation, vol. 5, no. 6, pp. 1452–1461, 2005. View at Publisher · View at Google Scholar · View at PubMed
  21. H. Zylberberg, B. Nalpas, F. Carnot et al., “Severe evolution of chronic hepatitis C in renal transplantation: a case control study,” Nephrology Dialysis Transplantation, vol. 17, no. 1, pp. 129–133, 2002. View at Google Scholar
  22. K. Watashi, M. Hijikata, M. Hosaka, M. Yamaji, and K. Shimotohno, “Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes,” Hepatology, vol. 38, no. 5, pp. 1282–1288, 2003. View at Publisher · View at Google Scholar · View at PubMed
  23. L. Alric, V. Di-Martino, J. Selves et al., “Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection,” Gastroenterology, vol. 123, no. 5, pp. 1494–1499, 2002. View at Google Scholar
  24. E. Muñoz De Bustillo, C. Ibarrola, F. Colina et al., “Fibrosing cholestatic hepatitis in hepatitis C virus-infected renal transplant recipients,” Journal of the American Society of Nephrology, vol. 9, no. 6, pp. 1109–1113, 1998. View at Google Scholar
  25. J. M. Morales, J. M. Campistol, A. Andrés, and J. L. Rodicio, “Hepatitis C virus and renal transplantation,” Current Opinion in Nephrology and Hypertension, vol. 7, no. 2, pp. 177–183, 1998. View at Publisher · View at Google Scholar
  26. H. Wéclawiack, N. Kamar, M. Mehrenberger et al., “Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts,” Nephrology Dialysis Transplantation, vol. 23, no. 3, pp. 1043–1047, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. S. J. Carbognin, N. M. Solomon, F. E. Yeo et al., “Acute renal allograft rejection following pegylated IFN-alpha treatment for chronic HCV in a repeat allograft recipient on hemodialysis: a case report,” American Journal of Transplantation, vol. 6, no. 7, pp. 1746–1751, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. O. Ozgur, S. Boyacioglu, H. Telatar, and M. Haberal, “Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C,” Nephrology Dialysis Transplantation, vol. 10, no. 11, pp. 2104–2106, 1995. View at Google Scholar · View at Scopus
  29. Y. Harihara, Y. Kurooka, T. Yanagisawa, K. Kuzuhara, O. Otsubo, and H. Kumada, “Interferon therapy in renal allograft recipients with chronic hepatitis C,” Transplantation Proceedings, vol. 26, no. 4, p. 2075, 1994. View at Google Scholar · View at Scopus
  30. N. Kamar, D. Ribes, J. Izopet, and L. Rostaing, “Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant,” Transplantation, vol. 82, no. 7, pp. 853–856, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. F. Fabrizi, G. Lunghi, V. Dixit, and P. Martin, “Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients,” Alimentary Pharmacology and Therapeutics, vol. 24, no. 10, pp. 1413–1422, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. G. P. Pageaux, M. N. Hilleret, V. Garrigues et al., “Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study,” Transplant International, vol. 22, no. 5, pp. 562–567, 2009. View at Publisher · View at Google Scholar · View at PubMed
  33. G. Barril, E. González Parra, and R. Alcázar, “Guías sobre enfermedades víricas en hemodiálisis,” Nefrología, vol. 24, supplement 2, p. 43, 2004. View at Google Scholar
  34. J. M. Cruzado, T. Casanovas-Taltavull, J. Torras, C. Baliellas, S. Gil-Vernet, and J. M. Grinyó, “Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance,” American Journal of Transplantation, vol. 3, no. 3, pp. 357–360, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. J. M. Campistol, N. Esforzado, and J. M. Morales, “Hepatitis C virus-positive patients on the waiting list for transplantation,” Seminars in Nephrology, vol. 22, no. 4, pp. 361–364, 2002. View at Google Scholar · View at Scopus
  36. L. Rostaing, E. Chatelut, J. L. Payen et al., “Pharmacokinetics of alpha IFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications,” Journal of the American Society of Nephrology, vol. 9, no. 12, pp. 2344–2348, 1998. View at Google Scholar · View at Scopus
  37. N. Kamar, O. Toupance, M. Buchler et al., “Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation,” Journal of the American Society of Nephrology, vol. 14, no. 8, pp. 2092–2098, 2003. View at Publisher · View at Google Scholar
  38. C. H. Liu, C. C. Liang, J. W. Lin et al., “Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study,” Gut, vol. 57, no. 4, pp. 525–530, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. M. Rendina, A. Schena, N. M. Castellaneta et al., “The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant,” Journal of Hepatology, vol. 46, no. 5, pp. 768–774, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. M. W. Russo, C. D. Goldsweig, I. M. Jacobson, and R. S. Brown Jr., “Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety,” American Journal of Gastroenterology, vol. 98, no. 7, pp. 1610–1615, 2003. View at Google Scholar · View at Scopus
  41. J. M. Cruzado, S. Gil-Vernet, G. Ercilla et al., “Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts,” Journal of the American Society of Nephrology, vol. 7, no. 11, pp. 2469–2475, 1996. View at Google Scholar · View at Scopus
  42. D. Roth, R. Cirocco, K. Zucker et al., “De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients,” Transplantation, vol. 59, no. 12, pp. 1676–1682, 1995. View at Google Scholar · View at Scopus
  43. J. M. Morales, J. Pascual-Capdevila, J. M. Campistol et al., “Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients,” Transplantation, vol. 63, no. 11, pp. 1634–1639, 1997. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Baid, M. Pascual, W. W. Williams Jr. et al., “Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients,” Journal of the American Society of Nephrology, vol. 10, no. 1, pp. 146–153, 1999. View at Google Scholar · View at Scopus
  45. G. S. Markowitz, J. T. Cheng, R. B. Colvin, W. M. Trebbin, and V. D. D'Agati, “Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy,” Journal of the American Society of Nephrology, vol. 9, no. 12, pp. 2244–2252, 1998. View at Google Scholar · View at Scopus
  46. N. Perico, D. Cattaneo, B. Bikbov, and G. Remuzzi, “Hepatitis C infection and chronic renal diseases,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 1, pp. 207–220, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. K. Kasuno, T. Ono, A. Matsumori et al., “Hepatitis C virus-associated tubulointerstitial injury,” American Journal of Kidney Diseases, vol. 41, no. 4, pp. 767–775, 2003. View at Google Scholar · View at Scopus
  48. M. Wörnle, H. Schmid, B. Banas et al., “Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis,” American Journal of Pathology, vol. 168, no. 2, pp. 370–385, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. J. Pérez-Calvo, N. Murashige, M. A. Fuertes et al., “The safety of rituximab in hepatitis C virus (HCV) positive patients,” Journal of Applied Research, vol. 4, no. 3, pp. 470–475, 2004. View at Google Scholar · View at Scopus
  50. F. Fabrizi, P. Messa, P. Martin, and B. Takkouche, “Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis,” International Journal of Artificial Organs, vol. 31, no. 8, pp. 675–682, 2008. View at Google Scholar · View at Scopus
  51. R. D. Bloom, V. Rao, F. Weng, R. A. Grossman, D. Cohen, and K. C. Mange, “Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus,” Journal of the American Society of Nephrology, vol. 13, no. 5, pp. 1374–1380, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. R. D. Bloom, G. Sayer, K. Fa, S. Constantinescu, P. Abt, and K. R. Reddy, “Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list,” American Journal of Transplantation, vol. 5, no. 1, pp. 139–144, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. R. D. Bloom and J. R. Lake, “Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients,” American Journal of Transplantation, vol. 6, no. 10, pp. 2232–2237, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. C. Manzanares, M. Moreno, F. Castellanos et al., “Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients,” Transplantation Proceedings, vol. 30, no. 4, pp. 1264–1265, 1998. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Corell, J. M. Morales, A. Mandroño et al., “Immunosuppression induced by hepatitis C virus infection reduces acute renal-transplant rejection,” Lancet, vol. 346, no. 8988, pp. 1497–1498, 1995. View at Google Scholar · View at Scopus
  56. D. Hestin, F. Guillemin, N. Castin, A. Le Faou, J. Champigneulles, and M. Kessler, “Pretransplant hepatitis C virus infection: a predictor of proteinuria after renal transplantation,” Transplantation, vol. 65, no. 5, pp. 741–744, 1998. View at Publisher · View at Google Scholar · View at Scopus
  57. J. P. Forman, N. Tolkoff-Rubin, M. Pascual, and J. Lin, “Hepatitis C, acute humoral rejection, and renal allograft survival,” Journal of the American Society of Nephrology, vol. 15, no. 12, pp. 3249–3255, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. F. Moreso, M. Ibernon, M. Gomà et al., “Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss,” American Journal of Transplantation, vol. 6, no. 4, pp. 747–752, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. D. Serón, M. Arias, J. M. Campistol, and J. M. Morales, “Late renal allograft failure between 1990 and 1998 in Spain: a changing scenario,” Transplantation, vol. 76, no. 11, pp. 1588–1594, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. J. Torres, J. M. Aguado, R. San Juan et al., “Hepatitis C virus, an important risk factor for tuberculosis in immunocompromised: experience with kidney transplantation,” Transplant International, vol. 21, no. 9, pp. 873–878, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. P. Burra, A. Buda, U. Livi et al., “Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?” European Journal of Gastroenterology and Hepatology, vol. 18, no. 10, pp. 1065–1070, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. J. M. Morales, J. M. Campistol, G. Castellano et al., “Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV,” Kidney International, vol. 47, no. 1, pp. 236–240, 1995. View at Google Scholar · View at Scopus
  63. S. Caillard, L. Y. Agodoa, E. M. Bohen, and K. C. Abbott, “Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis,” Transplantation, vol. 81, no. 6, pp. 888–895, 2006. View at Google Scholar
  64. G. A. Knoll, M. R. Tankersley, J. Y. Lee, B. A. Julian, and J. J. Curtis, “The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients,” American Journal of Kidney Diseases, vol. 29, no. 4, pp. 608–614, 1997. View at Google Scholar · View at Scopus
  65. K. C. Abbott, K. L. Lentine, J. R. Bucci, L. Y. Agodoa, T. G. Peters, and M. A. Schnitzler, “The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients,” American Journal of Transplantation, vol. 4, no. 12, pp. 2032–2037, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. M. K. Breitenfeldt, J. Rasenack, H. Berthold et al., “Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation,” Clinical Transplantation, vol. 16, no. 2, pp. 130–136, 2002. View at Publisher · View at Google Scholar
  67. H. Meier-Kriesche, A. O. Ojo, J. A. Hanson, and B. Kaplan, “Hepatitis C antibody status and outcomes in renal transplant recipients,” Transplantation, vol. 72, no. 2, pp. 241–244, 2001. View at Google Scholar · View at Scopus
  68. F. L. Luan, D. E. Schaubel, H. Zhang et al., “Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C,” Transplantation, vol. 85, no. 11, pp. 1601–1606, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. K. Watashi, M. Hijikata, M. Hosaka, M. Yamaji, and K. Shimotohno, “Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes,” Hepatology, vol. 38, no. 5, pp. 1282–1288, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. I. M. Mahmoud, M. A. Sobh, A. F. El-Habashi et al., “Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course,” Nephron Clinical Practice, vol. 100, no. 4, pp. c133–c139, 2005. View at Google Scholar
  71. I. M. Mahmoud, A. F. Elhabashi, E. Elsawy, A. A. El-Husseini, G. E. Sheha, and M. A. Sobh, “The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-Year prospective study,” American Journal of Kidney Diseases, vol. 43, no. 1, pp. 131–139, 2004. View at Publisher · View at Google Scholar
  72. F. G. Cosio, Z. Roche, A. Agarwal, M. E. Falkenhain, D. D. Sedmak, and R. M. Ferguson, “Prevalence of hepatitis C in patients with idiopathic glomerulopathies in native and transplant kidneys,” American Journal of Kidney Diseases, vol. 28, no. 5, pp. 752–758, 1996. View at Google Scholar
  73. J. M. Morales, J. M. Campistol, A. Andrés, and J. L. Rodicio, “Glomerular diseases in patients with hepatitis C virus infection after renal transplantation,” Current Opinion in Nephrology and Hypertension, vol. 6, no. 6, pp. 511–515, 1997. View at Google Scholar
  74. B. Domínguez-Gil, N. Esforzado, J. M. Campistol, A. Andrés, and J. M. Morales, “Use of hepatitis C-positive donors for kidney transplantation,” Transplantation Reviews, vol. 21, no. 4, pp. 195–203, 2007. View at Publisher · View at Google Scholar
  75. G. Basse, D. Ribes, N. Kamar et al., “Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients,” Transplantation Proceedings, vol. 38, no. 7, pp. 2308–2310, 2006. View at Publisher · View at Google Scholar · View at PubMed